Compare Adaptive Biotechnologies Corp (ADPT) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Trump Media and Technology Group Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.08 (market cap $3.33B), while Trump Media and Technology Group Corp trades at $8.25 (market cap $2.25B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | DJT | |
|---|---|---|
Market Cap | $3.33B | $2.25B |
Sector | Health | Media |
52-Week High | $22.37 | $19.86 |
52-Week Low | $10.24 | $7.06 |
Enterprise Value | $3.19B | $2.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DJT trades at $8.66, up 1.41% today, with a bullish technical signal from moving averages despite neutral oscillators. Fundamentally, the company reported minimal revenue of $3.68M in 2025 with a massive net loss of -$712M, resulting in negative profit margins and ROE. Recent news highlights significant stock declines, with the company's market value dropping nearly 75% from its peak amid strategic shifts including a planned merger with TAE Technologies.
The outlook remains highly speculative with severe profitability challenges offset by potential catalysts from the TAE merger. Key risks include persistent losses, minimal revenue growth, and high volatility. Institutional sentiment is cautious given the extreme valuation metrics and operational uncertainties facing the social media platform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
